Author

Stefano S Casola

IFOMORCID 0000-0001-5580-0986Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Adrian AndronacheiD· 1 shared Alberto BardelliiD· 1 shared Alessandra TucciiD· 1 shared Andrés J.M. FerreriiD· 1 shared Anojan SivacegaramiD· 1 shared Antonello Domenico CabrasiD· 1 shared Arianna Di NapoliiD· 1 shared Brian LeuzziiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrian AndronacheORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJan 23, 2026

Adrenergic signaling induces a pro-tumorigenic B cell state in colorectal cancer

Meike S. Thijssen, Simone L. Schonkeren, Linde Coolkens…·Veerle Melotte

This study shows adrenergic signaling promotes a pro-tumorigenic B cell state in colorectal cancer by altering their transcriptome and function, linking neuronal activity to immune responses and patient survival.

DOI 10.64898/2026.01.23.700260

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyBlood Cancer DiscoveryPeer-reviewedMay 22, 2025

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

Gabriele Varano, Silvia Lonardi, Paola Sindaco…·Stefano S Casola

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

10 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky